



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/054,647	01/22/2002	Robert Lawton	00-1278-C	9151

20306 7590 07/03/2002

MCDONNELL BOEHNEN HULBERT & BERGHOFF
300 SOUTH WACKER DRIVE
SUITE 3200
CHICAGO, IL 60606

EXAMINER

FORD, VANESSA L

ART UNIT	PAPER NUMBER
1645	

DATE MAILED: 07/03/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/054,647	LAWTON ET AL.
Examiner	Art Unit	
Vanessa L. Ford	1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 22 January 2002.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-6 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-6 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 3 and 4.

4) Interview Summary (PTO-413) Paper No(s). _____.

5) Notice of Informal Patent Application (PTO-152)

6) Other: _____.

DETAILED ACTION

Specification Objections

1. The specification is objected to because of the following informalities: *Ehrlichia* is the name of a genus and should be italicized. For example, page 10, line 17 and line 22.

2. The specification is objected to because of the following informalities: The use of trademarks throughout the specification. For example, page 17, line 22. Applicant is asked to review the specification for these type of errors and correction is required.

Claim Objections

3. Claims 4-6 are objected to because of the following informalities: *Ehrlichia* is the name of a genus and should be italicized.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 1-6 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. *This is a written description rejection.*

The specification broadly describes as a part of the invention a composition and an article of manufacture comprising the isolated polypeptide of SEQ ID No: 2 and variants thereof. The specification states that "variants in which amino acids of the polypeptides of the invention are substituted, deleted or added in any combination are contemplated by the invention". The specification also states " that naturally occurring variants and non-naturally occurring variants are included in the invention and may be produced by mutagenesis techniques or by direct synthesis" (page 7). Applicant has broadly described the invention as embracing any substitution, insertion or deletion change of amino acids throughout the length of the polypeptide sequence. Variants of SEQ ID No:2 correspond to sequences from other species, mutated sequences, allelic variants, splice variants, sequences that have a variant degree of identity (similarity, homology), and so forth. None of these sequences meet the written description provision of 35 U.S.C. 112, first, paragraph. The specification provides insufficient written description to support the genus encompassed by the claim. Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed.*" (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.)

With the exception of SEQ ID NO:2, the skilled artisan cannot envision the detailed chemical structure of the encompassed polypeptide regardless of the

Art Unit: 1645

complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993) and Amgen Inc. V. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. In Fiddes v. Baird, 30 USPQ2d 1481, 1483, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class. The specification provided only the bovine sequence.

Therefore, only SEQ ID NO: 2 but not the full breadth of the claim (or none of the sequences encompassed by the claim) meets the written description provision of 35 USC 112, first paragraph. The species specifically disclosed are not representative of the genus because the genus is highly variant. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115.)

5. Claims 1-6 rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a composition and an article of manufacture that comprise SEQ ID No:2, does not reasonably provide enablement for a composition or an article of manufacture that comprise variants of SEQ ID. No:2. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Claims 1-6 are directed to a composition and a article of manufacture comprising the isolated polypeptides of SEQ ID NO: 2 and variants thereof.

The specification is enabling only for the polypeptides of SEQ ID NO:2 as disclosed in the specification. The specification states that "variants in which amino acids of the polypeptides of the invention are substituted, deleted or added in any combination are contemplated by the invention". The specification also states " that naturally occurring variants and non-naturally occurring variants are included in the invention and may be produced by mutagenesis techniques or by direct synthesis" (page 7). The specification teaches that there are many tolerable and conservative amino acid substitutions which can be made that are not critical to protein function (pages 7-9). There is no guidance provided as to which amino acids can be added, deleted or substituted and the polypeptide would retain its biological function. The scope of the claims is not commensurate with the enablement provided by the disclosure with regard to the extremely large number of polypeptides broadly encompassed by the claims and the claims broadly encompass a significant number of inoperative species. Since the amino acid sequence of the polypeptide determines its structural and functional properties, predictability of which changes can be tolerated in a polypeptide's amino acid sequence and still retain similar activity/utility requires a knowledge with regard to which amino acids in the polypeptide's sequence, if any, are tolerant of modification and which are conserved (i.e. expected intolerant to modification) and detailed knowledge of the ways in which the polypeptide's structure relates to function. However, the problem of the prediction of polypeptide structure from

mere sequence data of a single polypeptide and in turn utilizing predicted structural determinations to ascertain functional aspects of the polypeptide and finally what changes can be tolerated with respect thereto is extremely complex and outside of the realm of routine experimentation.

While recombinant and mutagenesis techniques are known, it is not routine in the art to screen multiple substitutions or multiple modifications of other types and the positions within the polypeptide's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining similar activity are limited in any polypeptide and the result of such modifications is unpredictable based on the instant disclosure. One skilled in the art would expect any tolerance to modifications, e.g., multiple substitutions. The sequence of some polypeptides is highly conserved and one skilled in the art would not expect tolerance to any amino acid modification in such polypeptides.

Factors to be considered in determining whether undue experimentation is required, are set forth in In re Wands 8 USPQ2d 1400. They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art and (8) the breadth of the claims.

Applying the above test to the facts of record, it is determined that 1) no declaration under 37 C.F.R. 1.132 or other relevant evidence has been made of record establishing the amount of experimentation necessary, 2) insufficient direction or

guidance is presented in the specification with respect to selecting other antigens having claimed functional features, 3) the relative skill of those in the art is commonly recognized as quite high (post-doctoral level). One of skill in the art would require guidance, in order to make or use polypeptides that are variants of SEQ ID NO: 2 in a manner reasonable in correlation with the scope of the claims. Without proper guidance, the experimentation is undue.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claim 3 is indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 3 is indefinite because it recites "a polypeptide shown in SEQ ID No:2". It is unclear as to what the Applicant is referring?

7. Claim 5 is indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 5 is indefinite because it is unclear as to whether the Applicant is claiming a product or process. Clarification is required.

8. Claim 5 is indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 5 is indefinite because it recites "under conditions". It is unclear as to what the Applicant is referring?

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless —

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

9. Claims 1-6 are rejected under 35 U.S.C. 102(a) as anticipated by Waner et al (*J Vet Diagn Invest*, 2000, 12:240-244).

Claims 1-6 are drawn to a composition and article of manufacture comprising an isolated polypeptide shown in SEQ ID No:2 or variants thereof.

Waner et al teach a composition comprising culture growth medium and DH82 cells infected with Israeli isolate 611(page 240, 2nd column). Waner et al teach the use of a article of manufacture (i.e. a clinic ELISA test kit). Waner et al teach that *Ehrlichia canis* IgG antibody titers of serum samples were determined by using a commercial ELISA test kit containing plastic combs sensitized with *E. canis* antigen. Waner et al teach that the sera to be tested was incubated with the comb (containing antigen dots). Waner et al teach that after washing away unbound antibodies the comb were allowed to react with goat anti-dog IgG alkaline phosphatase conjugate. Waner et al teach that

bound antibodies were detected with a precipitating chromogen, 5-bromo-4chloro-3-indolyl phosphate and nitro-blue tetrazolium. The polypeptide sequence used in the composition would be inherent in the teachings of the prior art. The polypeptide sequence contained on the plastic comb (i.e. article of manufacture) would also be inherent in the teachings of the prior art. It is well known in the art to include packing material that comprises a label to indicate the intended use of the article of manufacture. The article of manufacture of Waner, et al appears to be the same as the claimed invention.

Since the Office does not have the facilities for examining and comparing applicant's composition and article of manufacture with the device of the prior art, the burden is on the applicant to show a novel or unobvious difference between the claimed product and the product of the prior art (i.e., that the composition and article of manufacture of the prior art does not possess the same material structural and functional characteristics of the claimed composition and article of manufacture). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

10. Claims 1-6 are rejected under 35 U.S.C. 102(b) as anticipated by Cadman et al (*Veterinary Record*, 1994, 135, 362).

Claims 1-6 are drawn to a composition and article of manufacture comprising an isolated polypeptide shown in SEQ ID No:2 or variants thereof.

Cadman et al teach an article of manufacture (i.e a cross dot blot apparatus), nitrocellulose paper coated with *E. canis* antigen. Cadman et al teach a composition comprising 0.7 µg of protein in TBS (page 362, 1st column). Cadman et al teach that test sera was incubated with the antigen (dots on nitrocellulose paper). Cadman et al teach that the bound antibody was detected with peroxidase-labeled goat anti-dog IgG and 4-chloronaphthol. The polypeptide sequence used in the composition would be inherent in the teachings of the prior art. The polypeptide sequence contained on the nitrocellulose membrane (i.e. article of manufacture) would also be inherent in the teachings of the prior art. It is well known in the art to include packing material that comprises a label to indicate the intended use of the article of manufacture. The composition and article of manufacture of Cadman, et al appears to be the same as the claimed invention.

Since the Office does not have the facilities for examining and comparing applicant's composition and article of manufacture with the composition and article of manufacture of the prior art, the burden is on the applicant to show a novel or unobvious difference between the claimed product and the product of the prior art (i.e., that the composition and article of manufacture of the prior art does not possess the same material structural and functional characteristics of the claimed composition and article of manufacture). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

11. Claims 1-6 are rejected under 35 U.S.C. 102(b) as anticipated by Zhi et al (*Journal of Clinical Microbiology*, June 1998, p. 1666-1673).

Claims 1-6 are drawn to a composition and article of manufacture comprising an isolated polypeptide shown in SEQ ID No:2 or variants thereof.

Zhi et al teach a composition comprising an affinity-purified protein in TBS that was blotted onto a nitrocellulose membrane and immersed in T-TBS containing 5% milk. Zhi et al teach an article of manufacture (i.e dot blot apparatus comprising a nitrocellulose membrane). Zhi et al teach that sera to be tested was diluted and incubated with the nitrocellulose membrane containing the dot of affinity-purified protein (i.e. polypeptide /antibody complex). Zhi et al teach that the affinity-purified protein was wash with T-TBS and incubated with peroxidase-conjugated affinity-purified anti-human IgG. Zhi et al further teach that the peroxidase-positive band was detected by immersing the nitrocellulose membrane in a developing solution indicating *Ehrlichia* infection (page 1668, 1st column). The polypeptide sequence used in the composition would be inherent in the teachings of the prior art. The polypeptide sequence contained on the nitrocellulose membrane (i.e. article of manufacture) would also be inherent in the teachings of the prior art. It is well known in the art to include packing material that comprises a label to indicate the intended use of the article of manufacture. The composition and article of manufacture of Zhi, et al appears to be the same as the claimed invention.

Since the Office does not have the facilities for examining and comparing applicant's composition and article of manufacture with the composition and article of

manufacture of the prior art, the burden is on the applicant to show a novel or unobvious difference between the claimed product and the product of the prior art (i.e., that the composition and article of manufacture of the prior art does not possess the same material structural and functional characteristics of the claimed composition and article of manufacture). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

12. Claims 1-6 are rejected under 35 U.S.C. 102(b) as anticipated by Rikihisa et al (*WO 99/13720, published March 25, 1999*).

Claims 1-6 are drawn to a composition and article of manufacture comprising an isolated polypeptide shown in SEQ ID No:2 or variants thereof.

Rikihisa et al teach immunogenic compositions comprising the isolated polypeptide of SEQ ID NO:2 and pharmaceutically acceptable adjuvants (page 12). Rikihisa et al teach an antigen (i.e. isolated polypeptide) used in a Western immunoblot analysis and a dot blot analysis to detect the presence of antibody to *E. canis* (page 17). The polypeptide of SEQ ID No: 2 is disclosed in Figure 19A). The article of manufacture (i.e. dot blot used in the dot blot analysis) would be inherent in the teachings of the prior art. It is well known in the art to include packing material that comprises a label to indicate the intended use of the article of manufacture. The composition and article of manufacture of Rikihisa, et al appears to be the same as the claimed invention.

Since the Office does not have the facilities for examining and comparing applicant's composition and article of manufacture with the composition and article of manufacture of the prior art, the burden is on the applicant to show a novel or unobvious difference between the claimed product and the product of the prior art (i.e., that the composition and article of manufacture of the prior art does not possess the same material structural and functional characteristics of the claimed composition and article of manufacture). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

Pertinent Prior Art

13. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure (*Unver et al, Journal of Clinical Microbiology, Dec 1999, p. 3888-3895* and *McBride et al, Journal of Clinical Microbiology, January 2001, p. 315-322*).

Status of Claims

14. No claims are allowed.

Conclusion

15. Any inquiry of the general nature or relating to the status of this general application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Office Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for the Group 1600 is (703) 308-4242.

Any inquiry concerning this communication from the examiner should be directed to Vanessa L. Ford, whose telephone number is (703) 308-4735. The examiner can normally be reached on Monday – Friday from 7:30 AM to 4:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached at (703) 308-3909


Vanessa L. Ford
Biotechnology Patent Examiner
June 26, 2002


LYNETTE R. F. SMITH
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600